Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol

Fig. 1

Scheme of this study protocol. CT, computed tomography; ECG, electrocardiogram; MRI, magnetic resonance imaging; PET, positron emission tomography; XP, X-ray photograph; CTCAE, common terminology criteria for adverse events; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; FDG, 18F-fluorodeoxyglucose; MSTS, Musculoskeletal Tumor Society

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us